Biliary Atresia in Children | NYU Langone Health
Experts at Hassenfeld Children’s Hospital at NYU Langone diagnose and treat babies with biliary atresia, which causes blockages in bile ducts.
Biological and Imaging Markers to Understand and Predict Progression of Joint Damage after Injury
This study aims to study joint health after an anterior cruciate ligament (ACL) (band of tissue in the knee) injury both in the short and long term. We will look at how the body responds to injury by measuring markers in synovial fluid (SF, a thick liquid located between your joints) and gathering knee images with magnetic resonance imaging (MRI).
Biology of Blood Cells in Healthy Volunteers
The purpose of the study is to investigate immune cell and platelet physiology in a healthy population, as immune response and platelet activity has been speculated to play a role in aneurysm formation.We hope to determine the baseline immune cell and platelet properties in a healthy population.
Biomarker and Edema Attenuation in IntraCerebral hemorrhage (BEACH)
This first-in-patient phase 2a pilot study will assess the safety and tolerability of MW01-6-189WH (hereafter called MW189) in patients with Intracerebral Hemorrhage (ICH). This study will monitor exploratory radiographic and clinical endpoints, explore the use of biochemical biomarkers to demonstrate target engagement and biological response to a potential new therapy targeted to neuroinflammation and synaptic dysfunction mechanisms.
Biomarker Liquid Observation Of Mothers (BLOOM)
The purpose of this study is to learn more about postpartum depression, a mental health problem that affects some women after they give birth. Mothers with postpartum depression can feel very sad, lose interest in things they used to enjoy, have trouble sleeping, have low self-esteem, feel guilty a lot, and have trouble thinking clearly. It can also affect how babies grow and develop emotionally and behaviorally in the long run. We are interested in finding biological predictors of postpartum depression in body fluids, including blood, saliva, and cerebrospinal fluid - the liquid surrounding the brain and spinal cord. After collecting these specimens during delivery, we will survey different biological molecules, looking for specific predictors of postpartum depression. We are looking for pregnant women scheduled to deliver by Cesarean section, in which accessing these body liquids is medically required. Women participating in our study will also be asked to fill out a short online survey a few times post-delivery. Our long-term goal is to use our results to predict which women are at risk for postpartum depression to be able to predict, prevent, and treat such mothers to promote their and their children's mental health.
Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726 (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study
This is a pilot study to see whether biomarkers called Tumor Mutation Burden (TMB) and Gene Expression Profiling (GEP) can be used to study the response of combination of cabozantinib and nivolumab drugs in patients with advanced melanoma or head and neck cancer who have progressed after prior anti-PD1-based treatment. Tumor mutational burden (TMB) measures the number of genetic changes happening in a tumor's DNA. Gene Expression Profiling (GEP) biomarkers are patterns of gene activity used to study the tumor response to the treatment. All participants will receive the same treatment- Nivolumab 480 mg in combination with Cabozantinib 40 mg. Cabozantinib is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that works by blocking the action of several tyrosine kinases, a type of protein that plays a key role in cancer cell growth and survival. Nivolumab is an immunotherapy drug that works by stimulating the body's own immune system to fight cancer cells. All patients will be tested for TMB and GEP biomarkers and divided into four biological groups based on TMB and GEP scores (hi/hi, hi/lo, lo/hi, or lo/lo). All patients will have special scans done to see how their cancer is changing in response to the treatment and how long it takes the cancer to come back. Patients will have blood samples taken for special testing of circulating tumor DNA (ctDNA) to check for TMB and other biomarkers. All patients will be closely monitored for potential side effects and safety concerns.
Biomarkers for preterm births using non-invasive samples
Preterm delivery is a leading cause of neonatal mortality and continues to be a major public health concern. Although some pregnant women will present with preterm labor (uterine contractions), most will not progress to actual preterm delivery (birth). Identifying which pregnant women presenting with preterm labor that will actually progress to preterm delivery is a challenge for clinicians. Studies have demonstrated that measuring biomarkers (inflammatory mediators, microRNA and cytokines) in intra-uterine tissues (placenta, amniotic membranes and amniotic fluids) can predict preterm labor progression to delivery. However obtaining such samples are invasive and can be dangerous. The overall goal of this study is to identify biomarkers from samples from non-invasive sites that will increase the clinician’s ability to identify patients who present with second trimester preterm labor (uterine contractions) that will progress to preterm delivery. Specifically, we will measure biomarkers from non-invasive samples (blood, urine, vaginal secretions and saliva) in pregnant women (at less than 34 weeks gestation) presenting to NYU Winthrop Hospital with preterm labor (contractions). We will compare two groups; 1) pregnant women with preterm labor that deliver within 3 days after admission to the hospital vs. 2) women with preterm labor that deliver more than 3 days after admission. We will need 60 samples from group 1. Since approximately 25% of pregnant women presenting with preterm labor will actually end with preterm delivery, we will enroll a total of 240 subjects. After consent is obtained, samples (blood, urine, vaginal secretions and saliva) will be collected at the time of the hospital admission. If the patient did not progress to preterm delivery and was discharged home, no more samples will be obtained. If the patient continued to be admitted in the hospital for observation, weekly samples will be obtained whenever possible. When subjects progress to active labor and delivery, samples will be collected (blood, urine, vaginal secretions and saliva) as well as placenta/fetal membranes after delivery. The collected samples will be transported, processed and stored at the PI lab at NYU Winthrop Hospital. Biomarkers (such as inflammatory mediators, cytokines and microRNA) will be evaluated to predict preterm delivery in these pregnant women. A secondary objective is to correlate the inflammatory biomarkers obtained during pregnancy with the neonatal outcome (obtained by review of the neonatal medical records).
BiorEsorbable SiroLimus-ElutIng Scaffold TreatmEnt for Below The Knee Disease ELITE-BTK Trial
The purpose of this research is to is to evaluate the investigational MAGNITUDE® Bioresorbable Drug-Eluting Scaffold (MAGNITUDE Scaffold) to treat narrowed or blocked leg arteries below the knee compared to the standard of care with balloon angioplasty.
BIOTRONIK Conduction System Pacing with the Solia Lead Study
This is a prospective, non-randomized, multi-center, IDE clinical study that will enroll patients who are candidates for implantation of a BIOTRONIK single, dual, or CRT-pacemaker system according to standard guidelines and for whom an LBB area pacing implant is planned. The purpose of the BIO-CONDUCT investigational device exemption (IDE) study is to demonstrate the safety and effectiveness of the BIOTRONIK Solia S pacing lead when implanted in the left bundle branch (LBB) area.
Bipolar Disorder | NYU Langone Health
NYU Langone mental health specialists offer expert treatment for bipolar disorder.